Clinical trials’ integrity and utility is routinely undermined by flaws in design, methods, publication and interpretation, a paper published in Trials concludes.
While the paper does not present new data, its summary of salient factors and the corresponding literature makes it a valuable point of departure for researchers and campaigners in the field of evidence-based medicine.
Pharma-sponsored drug and device trial studies are about 30% more likely to have results and conclusions that favour the sponsor, a new Cochrane Library review has found.
The review found that studies run by pharma companies routinely show greater efficacy and less harms. The authors outlined some common ways in which sponsors can influence study outcomes, including the framing...